var data={"title":"Methimazole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methimazole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6552?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methimazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methimazole: Patient drug information&quot;</a> and <a href=\"topic.htm?path=methimazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methimazole: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24520218\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tapazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194315\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dom-Methimazole;</li>\n      <li>PHL-Methimazole;</li>\n      <li>Tapazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194348\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antithyroid Agent;</li>\n      <li>\n        Thioamide</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194318\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism:</b> Oral: Initial: 15 to 60 mg/day depending on severity of disease; usual maintenance dose: 5 to 15 mg/day. <b>Note:</b> The manufacturer suggests dividing the daily dose into 3 equal administrations; however, administration as a single daily dose or in 2 divided doses (for doses &gt;30 mg/day) may be preferred (Ross 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjust dosage as required to achieve and maintain serum T<sub>3</sub>, T<sub>4</sub>, and TSH levels in the normal range. An elevated T<sub>3</sub> may be the sole indicator of inadequate treatment. An elevated TSH indicates excessive antithyroid treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism associated with Graves disease (off label) (Ross 2016):</b> Oral: <b>Note:</b> Individualize dose based on serum free T<sub>4</sub> and T<sub>3</sub> levels and clinical status to restore euthyroidism and minimize adverse effects. Adjunctive therapy with potassium iodide may be beneficial in controlling hyperthyroidism and may allow lower initial dosages of methimazole to be used (Sato 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 10 to 30 mg once daily; based on free T<sub>4</sub> levels, lower doses (eg, 5 mg/day) or higher doses (eg, 40 mg/day) may be considered however initial doses &gt;30 mg/day are associated with increased adverse effects. In patients with severe disease, administering the daily dose in 2 divided doses (eg, 15 to 20 mg twice daily) may increase efficacy (methimazole duration of action may be less than 24 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following recommendations may be considered to guide initial dosing based on free T<sub>4</sub> levels:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to 1.5 times ULN: 5 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;1.5 to 2 times ULN: 10 to 20 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;2 times ULN: 30 to 40 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual maintenance: 5 to 10 mg once daily for a total of 12 to 18 months, then discontinue if thyroid function tests (eg, TSH, thyrotropin receptor antibody [TRAb]) are normal at that time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Iodine-induced thyrotoxicosis (off-label use):</b> Oral: 20 to 40 mg daily given either once or twice daily (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxicosis or thyroid storm (off-label use):</b> Oral: <b>Note:</b> Recommendations vary; use in combination with other specific agents. Dosages of 20 to 25 mg every 6 hours have been used; once stable, dosing frequency may be reduced to once or twice daily (Nayak 2006). The American Thyroid Association recommends 60 to 80 mg/day (Ross 2016). Rectal administration has also been described (Nabil 1982).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyrotoxicosis, type 1 amiodarone-induced (off-label use):</b> Oral: 40 mg once daily to restore euthyroidism (generally 3 to 6 months). If high doses continue to be required, dividing the dose may be more effective. <b>Note:</b> Use in combination with a corticosteroid if etiology of thyrotoxicosis (eg, type 1 or type 2) cannot be unequivocally determined or if patient is too clinically unstable to allow a trial of monotherapy (Ross 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194331\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=methimazole-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methimazole: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism:</b> Children and Adolescents: Oral: Initial: 0.4 mg/kg/day; maintenance: 0.2 mg/kg/day <b>Note:</b> The manufacturer suggests dividing the daily dose into 3 equal administrations; however, administration as a single daily dose or in 2 divided doses (for doses &gt;30 mg/day) may be preferred (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperthyroidism associated with Graves disease (off-label) (Ross 2016):</b> Infants, Children, and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: Weight-based dosing: 0.2 to 0.5 mg/kg once daily (range: 0.1 to 1 mg/kg/day); in severe cases, initial doses that are 50% to 100% higher may be used; once patient is euthyroid, reduce dose by 50% or more and continue for a total duration of therapy of 1 to 2 years; may then discontinue or reduce dose to assess if patient is in remission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">The following fixed dosing approach may also be considered (using one-quarter, one-half, or whole tablets) (Ross 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 1.25 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 5 years: 2.5 to 5 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 10 years: 5 to 10 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 10 to 18 years: 10 to 20 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194319\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570395\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16570396\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194291\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tapazole: 5 mg, 10 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194276\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5360379\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Rectal: In thyrotoxic crisis, rectal administration has been described (Nabil 1982).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132856\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and preparation in a controlled device or use of ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator) for compounding; if not prepared in a controlled device, respiratory and eye/face protection are recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194293\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hyperthyroidism:</b> Treatment of hyperthyroidism in patients with Graves&rsquo; disease or toxic multinodular goiter (surgery or radioactive iodine therapy is not appropriate); amelioration of hyperthyroid symptoms in preparation for thyroidectomy or radioactive iodine therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730657\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Iodine-induced thyrotoxicosis; Thyroid storm or thyrotoxicosis; Thyrotoxicosis (type 1 amiodarone-induced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194356\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MethIMAzole may be confused with metOLazone</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194283\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema, hypersensitivity angiitis (including ANCA-positive), periarteritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness, headache, neuritis, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Goiter, hypoglycemic coma, insulin autoimmune syndrome, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Ageusia, constipation, enlargement of salivary glands, epigastric distress, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, granulocytopenia, hypoprothrombinemia, leukopenia, lymphadenopathy, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic necrosis, hepatitis, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, lupus-like syndrome, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Nephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194296\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to methimazole or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194280\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding:  May cause hypoprothrombinemia and bleeding. Monitoring is recommended, especially before surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: May cause significant bone marrow depression; the most severe manifestation is agranulocytosis. Aplastic anemia, thrombocytopenia, and leukopenia may also occur. Use with caution with concomitant use of other drugs known to cause myelosuppression (particularly agranulocytosis). Monitor patients closely; discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatitis: Antithyroid agents have been associated with rare but severe dermatologic reactions. Discontinue in the presence of exfoliative dermatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fever: Discontinue in the presence of unexplained fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Hepatotoxicity (including acute liver failure)  may occur. Symptoms suggestive of hepatic dysfunction (eg, anorexia, pruritus, right upper quadrant pain) should prompt evaluation. Discontinue in the presence of hepatitis and clinically significant hepatic abnormality, including transaminase &gt;3 times upper limit of normal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypothyroidism: May cause hypothyroidism; routinely monitor TSH and free T<sub>4</sub> levels, adjust dose to maintain euthyroid state.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lupus-like syndrome:  A lupus-like syndrome may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vasculitis: ANCA-positive vasculitis may develop during therapy; discontinue use in the presence of vasculitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194344\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak), CYP2C9 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194285\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9627&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): MethIMAzole may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194287\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194299\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Methimazole crosses the placenta. Birth defects have been observed in neonates exposed to maternal methimazole in the first trimester of pregnancy and include anomalies of the upper gastrointestinal tract (esophageal atresia or tracheoesophageal fistula), respiratory tract (choanal atresia), skin (aplasia cutis), and facial dysmorphism. Additional abdominal wall defects (umbilicocele), ventricular septal defects, and defects of the eye and urinary system have also been reported (Alexander 2017). Hypothyroidism may occur in the newborn.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Uncontrolled maternal hyperthyroidism may result in adverse neonatal and maternal outcomes. Antithyroid drugs are the treatment of choice for the control of hyperthyroidism during pregnancy, although recommendations for specific agents vary by guideline (ACOG 2015; Alexander 2017; De Groot 2012). Dose requirements of methimazole may be decreased as pregnancy progresses. To prevent adverse pregnancy outcomes, maternal TT4/FT4 should be at or just above the pregnancy specific upper limit of normal (Alexander 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194300\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Methimazole is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of methimazole is 24% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 0.2 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of methimazole was calculated using a milk concentration of 0.32 mcg/mL, providing an estimated daily infant dose via breast milk of 0.048 mg/kg/day and compared to an infant therapeutic dose of 0.2 mg/day. This milk concentration was obtained following maternal administration of a single dose of methimazole 15 mg. The half-life of methimazole in breast milk was ~4 hours (Abe 1995).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Toxicity was not observed in a long-term study of breastfed infants whose mothers were receiving treatment with methimazole. The treatment of hyperthyroidism in breastfeeding women is the same as nonbreastfeeding women. The lowest effective dose should be used; maternal doses of methimazole &le;20 mg/day are advised in breastfeeding women. Infants exposed to antithyroid medications via breast milk should be monitored for adequate growth and development (Alexander 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194289\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Signs and symptoms of illness (ie fever, sore throat, skin eruptions, general malaise)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CBC with differential (baseline and if development of febrile illness or pharyngitis occurs); prothrombin time (especially before surgical procedures), liver function tests (bilirubin, alkaline phosphatase, ALT, AST at baseline and if symptoms of liver injury occur (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid function tests:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TSH (periodically throughout treatment, may remain suppressed for several months after starting therapy) (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum free T<sub>4</sub> and total T<sub>3</sub> 2 to 6 weeks after initiation, repeat in 4 to 6 weeks if dose is adjusted and then every 2 to 3 months once euthyroid levels are achieved (with long term therapy [ie, &gt;18 months] may extend interval to every 4 to 6 months); if TRAb is negative, thyroid function tests should be monitored every 2 to 3 months for the first 6 months after discontinuing therapy, then at 4- to 6-month intervals for the next 6 months, then every 6 to 12 months thereafter (Ross 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">TRAb (prior to stopping medication, elevation at the end of therapy decreases likelihood of remission) (Ross 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194279\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland; blocks synthesis of thyroxine and triiodothyronine (T<sub>3</sub>); does not inactivate circulating T<sub>4</sub> and T<sub>3</sub></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194295\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antithyroid: 12 to 18 hours (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 36 to 72 hours (Clark  2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Almost complete (Clark  2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Concentrated in thyroid gland</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: None (Cooper 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~93% (Clark 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 4 to 6 hours (Clark  2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours (Clark 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194298\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MethIMAzole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $44.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $76.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tapazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $245.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $424.16</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038676\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Athyrazol (HR);</li>\n      <li>Based (TW);</li>\n      <li>Danantizol (AR, PY);</li>\n      <li>Favistan (AT, CZ, DE, HR, HU, PY);</li>\n      <li>Mercaptizol (IL);</li>\n      <li>Methimazol (PL);</li>\n      <li>Methizol (DE);</li>\n      <li>Metibasol (PT);</li>\n      <li>Metizol (PL);</li>\n      <li>Metothyrin (HU);</li>\n      <li>Strumazol (BE, LU, NL);</li>\n      <li>Tapazol (BR, CO, PE, VE);</li>\n      <li>Tapazole (BB, CH, IT, LB, PH, TH);</li>\n      <li>Tapdin (PH);</li>\n      <li>Tapel (LK);</li>\n      <li>Thacapzol (SE);</li>\n      <li>Thiamazol Henning (AT, DE);</li>\n      <li>Thycaprol (DK);</li>\n      <li>Thyrozol (BG, CL, DE, LU, PL, VN);</li>\n      <li>Timazol (TH);</li>\n      <li>Tirodril (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Abe Y, Sato H, Sakai H et al. Antithyroid treatment of maternal hyperthyroidism during lactation. 11th International Thyroid Congress. Toronto, Ontario, Canada, September 10-15, 1995. Abstracts. <i>Thyroid</i>. 1995;5(Suppl 1):S1-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/7580275/pubmed\" target=\"_blank\" id=\"7580275\">7580275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. <i>Thyroid</i>. 2017;27(3):315-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/28056690/pubmed\" target=\"_blank\" id=\"28056690\">28056690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists, ACOG Practice Bulletin, Clinical Management Guidelines for Obstetrician-Gynecologists, Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001), &ldquo;Thyroid Disease in Pregnancy,&rdquo; <i>Obstet Gynecol</i>, 2002, 100(2):387-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/12166417/pubmed\" target=\"_blank\" id=\"12166417\">12166417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 148: Thyroid disease in pregnancy. <i>Obstet Gynecol.</i> 2015;125(4):996-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/25798985/pubmed\" target=\"_blank\" id=\"25798985\">25798985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark SM, Saade GR, Snodgrass WR, et al, &ldquo;Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,&rdquo; <i>Ther Drug Monit</i>, 2006, 28(4):477-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/16885714/pubmed\" target=\"_blank\" id=\"16885714\">16885714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper DS, &quot;Antithyroid Drugs,&quot; <i>N Engl J Med</i>, 2005, 352(9):905-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/15745981/pubmed\" target=\"_blank\" id=\"15745981\">15745981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Groot L, Abalovich M, Alexander EK, et al, &ldquo;Management of Thyroid Dysfunction During Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(8):2543-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/22869843/pubmed\" target=\"_blank\" id=\"22869843\">22869843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamor GH and Lafdjian A, &ldquo;Dualistic Thiourea Moiety Taste Response of Methimazole,&rdquo; <i>J Pharm Sci</i>, 1967, 56(6):777-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/4166527/pubmed\" target=\"_blank\" id=\"4166527\">4166527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson DG and Campbell S, &ldquo;Hormonal and Metabolic Agents,&rdquo; <i>Geriatric Pharmacology</i>, Bressler R and Katz MD, eds, New York, NY: McGraw-Hill, 1993, 427-50.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nabil N, Miner DJ, and Amatruda JM, &ldquo;Methimazole: An Alternative Route of Administration,&rdquo; <i>J Clin Endocrinol Metab</i>, 1982, 54(1):180-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/7054215/pubmed\" target=\"_blank\" id=\"7054215\">7054215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nayak B and Burman K, &ldquo;Thyrotoxicosis and Thyroid Storm,&rdquo; <i>Endocrinol Metab Clin North Am</i>, 2006, 35(4):663-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/17127140/pubmed\" target=\"_blank\" id=\"17127140\">17127140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozaki N, Miura Y, Sakakibara A, et al, &ldquo;A Case of Hypersensitivity Syndrome induced by Methimazole for Graves' Disease,&rdquo; <i>Thyroid</i>, 2005, 15(12):1333-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/16405404/pubmed\" target=\"_blank\" id=\"16405404\">16405404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raby C, Lagorce JF, Jambut-Absil AC, et al, &ldquo;The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide,&rdquo; <i>Endocrinology</i>, 1990, 126(3):1683-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/1689656/pubmed\" target=\"_blank\" id=\"1689656\">1689656</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27521067\"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi: 10.1089/thy.2016.0229.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/27521067/pubmed\" target=\"_blank\" id=\"27521067\">27521067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25178068\"></a>Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. <i>Thyroid</i>. 2015;25(1):43-50. doi: 10.1089/thy.2014.0084.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/25178068/pubmed\" target=\"_blank\" id=\"25178068\">25178068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shiroozu A, Okamura K, Ikenoue H, et al, &quot;Treatment of Hyperthyroidism With a Small Single Daily Dose of Methimazole,&quot; <i>J Clin Endocrinol Metab</i>, 1986, 63(1):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/3011835/pubmed\" target=\"_blank\" id=\"3011835\">3011835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stagnaro-Green A, Abalovich M, Alexander E, et al, &quot;Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,&quot; <i>Thyroid</i>, 2011, 21(10):1081-125.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methimazole-drug-information/abstract-text/21787128/pubmed\" target=\"_blank\" id=\"21787128\">21787128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tapazole (methimazole) [prescribing information]. New York, NY: Pfizer Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9627 Version 155.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24520218\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F194315\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F194348\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F194318\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F194331\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F194319\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16570395\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16570396\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F194291\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F194276\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5360379\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132856\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F194293\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730657\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F194356\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F194283\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F194296\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F194280\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F194344\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F194285\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F194287\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F194299\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F194300\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F194289\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F194279\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F194295\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F194298\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038676\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9627|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methimazole-patient-drug-information\" class=\"drug drug_patient\">Methimazole: Patient drug information</a></li><li><a href=\"topic.htm?path=methimazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Methimazole: Pediatric drug information</a></li></ul></div></div>","javascript":null}